公开(公告)号：US20070031426A1

公开(公告)日：2007-02-08

申请号：US11496392

申请日：2006-07-31

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  G01N33/574 ,  C12N5/06 ,  C07K16/30

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/73

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20060263372A1

公开(公告)日：2006-11-23

申请号：US11462092

申请日：2006-08-03

申请人： David Young ,  Susan Hahn ,  Helen Findlay

发明人： David Young ,  Susan Hahn ,  Helen Findlay

IPC分类号： A61K39/395

CPC分类号： C07K16/3015 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/3069

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20050002940A1

公开(公告)日：2005-01-06

申请号：US10891866

申请日：2004-07-15

申请人： David Young ,  Susan Hahn ,  Helen Findlay

发明人： David Young ,  Susan Hahn ,  Helen Findlay

IPC分类号： A61K51/10 ,  A61P35/00 ,  C07K16/00 ,  C07K16/30 ,  C12N5/18 ,  G01N33/574 ,  C12Q1/68 ,  A61K39/395

CPC分类号： C07K16/3046 ,  A61K51/1045 ,  A61K51/1051 ,  A61K51/1096 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  G01N33/574 ,  G01N33/57484

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20070202041A1

公开(公告)日：2007-08-30

申请号：US11709444

申请日：2007-02-22

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Daad Sayegh

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Daad Sayegh

IPC分类号： A61K51/00 ,  A61K39/395 ,  A61K38/21 ,  C07K16/30 ,  C07K16/46

CPC分类号： C07K16/30 ,  A61K47/6851 ,  A61K51/1045 ,  A61K2039/505

摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

公开(公告)号：US20070202113A1

公开(公告)日：2007-08-30

申请号：US11709676

申请日：2007-02-22

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Luis DaCruz ,  Alison Ferry

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Luis DaCruz ,  Alison Ferry

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K16/30

CPC分类号： C07K16/30 ,  A61K47/6851 ,  A61K51/1045 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  G01N33/57484

摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

公开(公告)号：US20070053836A1

公开(公告)日：2007-03-08

申请号：US11592516

申请日：2006-11-03

申请人： David Young ,  Susan Hahn ,  Helen Findlay

发明人： David Young ,  Susan Hahn ,  Helen Findlay

IPC分类号： A61K51/00 ,  A61K39/395

CPC分类号： G01N33/566 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6849 ,  A61K49/0058 ,  A61K51/1027 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/00 ,  C07K16/2884 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/73 ,  G01N33/5011 ,  G01N33/5014 ,  G01N33/5082 ,  G01N33/56972 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  A61K2300/00

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.

摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用癌变疾病修饰抗体（CDMAB）或其衍生物，任选地与一种或多种化学治疗剂组合，作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMABs的结合测定法。

公开(公告)号：US20050100542A1

公开(公告)日：2005-05-12

申请号：US10810165

申请日：2004-03-26

申请人： David Young ,  Susan Hahn ,  Helen Findlay

发明人： David Young ,  Susan Hahn ,  Helen Findlay

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P35/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  G01N33/50 ,  G01N33/566 ,  G01N33/567 ,  G01N33/569 ,  G01N33/574 ,  C12N5/06

CPC分类号： G01N33/566 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6849 ,  A61K49/0058 ,  A61K51/1027 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/00 ,  C07K16/2884 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/73 ,  G01N33/5011 ,  G01N33/5014 ,  G01N33/5082 ,  G01N33/56972 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  A61K2300/00

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.

摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMABs的结合测定法。

公开(公告)号：US20050027106A1

公开(公告)日：2005-02-03

申请号：US10630416

申请日：2003-07-28

申请人： David Young ,  Susan Hahn ,  Helen Findlay

发明人： David Young ,  Susan Hahn ,  Helen Findlay

IPC分类号： A61P35/00 ,  C07K16/30 ,  G01N33/569 ,  G01N33/574

CPC分类号： G01N33/56966 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/303 ,  C07K16/3046 ,  C07K16/3069 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57449

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20060269481A1

公开(公告)日：2006-11-30

申请号：US11493407

申请日：2006-07-26

申请人： David Young ,  Susan Hahn ,  Helen Findlay ,  Luis daCruz ,  Daad Sayegh ,  Sheung Fan ,  Ronnie Poon ,  Terence Lee

发明人： David Young ,  Susan Hahn ,  Helen Findlay ,  Luis daCruz ,  Daad Sayegh ,  Sheung Fan ,  Ronnie Poon ,  Terence Lee

IPC分类号： A61K51/00 ,  G01N33/574 ,  A61K39/395

CPC分类号： G01N33/57438 ,  A61K51/1045 ,  A61K51/1051 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/303 ,  G01N2500/00

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

公开(公告)号：US20060216235A1

公开(公告)日：2006-09-28

申请号：US11370255

申请日：2006-03-07

申请人： David Young ,  Susan Hahn ,  Helen Findlay

发明人： David Young ,  Susan Hahn ,  Helen Findlay

IPC分类号： A61K51/00 ,  A61K39/395 ,  C07K16/30 ,  C07K16/46

CPC分类号： C07K16/3015 ,  A61K47/6855 ,  A61K47/6869 ,  A61K51/1051 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.